Clinitech Laboratory Ltd

Clinitech Laboratory Limited trading window closed from Oct 01, 2026 for half-year ended Sep 30, 2026; will reopen 48 hours after the declaration of the financial results.

AGM Details

• Date and time: 24 September 2026 at 11:30 IST; mode: VC/OAVM.
• Record/book closure dates not disclosed.

Key Resolutions & Outcomes

• Resolution 1: Adoption of financial statements; ordinary; passed with 70.71% in favour.
• Resolution 2: Re-appointment of director by rotation; ordinary; passed.
• Resolution 3: Approval of related party transactions involving director; special; passed.

Dividend

• No dividend proposed or declared.

AGM Details

• AGM held Sept 24, 2026 at 11:30 IST via VC/OAVM.
• Remote e-voting: Sept 21–23, 2026; cut-off Sept 17, 2026.
• Proxy attendance not available due to VC/OAVM.
• Meeting concluded at 12:00 Noon IST.

Key Resolutions

• Resolution 1: Adopt standalone and consolidated financial statements for year ended 31 March 2026.
• Resolution 2: Re-appoint Ashutosh Jagdish Nayak as director retiring by rotation.
• Resolution 3: Approve related party transactions with director-interested party.

Voting Status

• Voting results awaited; consolidated Scrutinizers' report to be disseminated.
• E-voting during AGM open; results to be uploaded later.

Director Changes

• Director Ashutosh Jagdish Nayak re-appointed; retires by rotation.

Material Related Party Transactions

• Approval of related party transactions with a director-interested party under Section 185.

Key dates

• Book closure: Sep 18, 2025 to Sep 24, 2026 (both days inclusive) for 16th AGM.
• Purpose: 16th Annual General Meeting.
• E-voting cut-off: Sep 17, 2026.
• E-voting period: Sep 21, 2026 09:00 IST to Sep 23, 2026 17:00 IST.
• AGM date: Sep 24, 2026 at 11:30 IST via VC/OAVM.

Financials (Standalone)

• Standalone revenue from operations reached 947.50 lakhs.
• Total standalone revenue stood at 966.31 lakhs.
• Net profit after tax was 42.25 lakhs.
• Basic earnings per share: 1.85.
• Dividend declared for FY2025-26: none.
• Cash and cash equivalents: 206.46 lakhs.

Subsidiaries & IPO

• Two subsidiaries formed in FY25-26: Medicarenx and Analog IVD.
• Each subsidiary is 60% owned.
• No material subsidiaries as of 31 Mar 2026.
• IPO proceeds raised: 578.30 lakhs; utilized 528.30; unutilized 50.00.

Capital structure & liquidity

• Standalone long-term borrowings: 35.76; consolidated 53.75.
• Current ratio: 7.04x.
• Trade payables: 39.95 standalone; 48.35 consolidated.
• Cash and cash equivalents: 206.46 standalone; 211.22 consolidated.
• Issued share capital: 228.24 lakhs.

Governance

• Board: 6 directors; 2 executive, 4 non-executive.
• Independent directors: 3; 10 board meetings in FY25-26.
• Audit Committee: 3 independent directors; 9 meetings.
• Secretarial audit: Deep Shukla & Associates.

Management & risk

• Indian diagnostic sector shows growth through automation and digital labs.
• Risks include regulatory changes, pricing, competition, and cybersecurity.
• Management aims to expand services via subsidiaries and upgrades.
• Digital health adoption supports long-term diagnostic growth.

Audits & compliance

• Statutory auditors: Kale Malde & Co.; Internal auditors: Kalpesh Khatri & Associates.
• Secretarial auditor: Deep Shukla & Associates; no adverse auditor remarks.

AGM & notices

• 16th AGM to be held Sep 24, 2026 via VC/OAVM.
• Notice and annual report disseminated electronically; available to shareholders.

Key board decisions

• Approved reappointment of director retiring by rotation.
• Approved Board's report for FY 2025-26 and annexures.
• Approved notice for the 16th AGM with date, time, venue.
• Finalized book-closure dates for the forthcoming AGM.
• Appointed Mr. Deep Shukla, Practising Company Secretary, as Scrutinizer for voting.

Meeting Details

• Date: August 17, 2026
• Time: 11:30 AM IST
• Mode: Video conferencing

Key Agenda Items

• To consider and approve appointment of a director retiring by rotation.
• To approve the Board's report for FY 2025-26, including annexures.
• To consider and approve the notice for 16th AGM and book-closure dates.
• To finalize the appointment of Mr. Deep Shukla as Scrutinizer for voting.

Other Notes

• Notice confirms August 17, 2026 board meeting via video conferencing.

Regulation 74(5) status

• RTA confirms Regulation 74(5) not applicable; entire holding dematerialised, no rematerialisation requests in quarter ended 30 June 2026.